Kuanysh Ospanov Appointed as Vice President of STADA Eurasia, Succeeding Arminas Matsevichus

Tashkent, Uzbekistan (UzDaily.com) — Kuanysh Ospanov has been appointed as Vice President of STADA Eurasia, replacing Arminas Matsevichus, who led the region for over five years.

The company noted that it will continue strengthening its position in over-the-counter (OTC) medicines and consumer healthcare products, as well as expanding its generics and specialized pharmaceuticals portfolio.

The appointment was officially announced on 17 February 2026, in Almaty. Kuanysh Ospanov brings extensive management experience from international pharmaceutical companies, including Sanofi and Haleon.

He graduated from Kazakh Economic University with a degree in Economics and Finance and earned a bachelor’s degree in Management and Business Administration from the Rochester Institute of Technology.

Ospanov’s main task as head of STADA Eurasia will be to further consolidate the company’s leadership in the CNS and OTC segments, while also developing its presence in generics and specialized medicines, including biosimilars.

“STADA has achieved impressive growth in the region over the past years. I am excited to contribute to the company’s development and, together with our professional team, ensure stable business growth, caring for people’s health and remaining a trusted partner in the healthcare system,” Ospanov emphasized.

The company expressed its gratitude to Arminas Matsevichus for more than five years of effective leadership in the Eurasia region, doubling business growth from 2023 to 2025 and achieving sustainable results.

STADA is an international pharmaceutical company with over 130 years of history, focused on healthcare and building trusted relationships with partners and consumers. Its key areas include consumer healthcare products, generics, and specialized medicines, including biosimilars. STADA products are available in 120 countries worldwide.

The CIS region was established as an independent business unit and renamed “Eurasia” in 2022, reporting directly to the headquarters in Germany. The regional headquarters is located in Almaty. Legal entities of STADA Arzneimittel AG are registered in the region, including in Kazakhstan.

Since 1 April 2023, STADA has represented Sanofi’s portfolio of OTC products in the region. Approximately 500 employees work in the Eurasia division.